AzTrials
AzTrials

Osteo Arthritis KneePhase 4NCT04635176

Comparing Local Anesthesia With and Without iPACK Block

A Phase 4 study testing Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone) in people with Osteo Arthritis Knee and Analgesia, run by University of Calgary at 1 site in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Total knee arthroplasty is an effective surgical intervention for patients with chronic osteoarthritis commonly performed worldwide. Postoperative pain management has been a key focus in patient care for this procedure. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
10 participants
Where
1 siteCanada
Study dates
30 Oct 2022to 27 May 2026
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients scheduled for elective unilateral TKA
  • Planned for regional anesthesia for the procedure
  • Age >=18

Who cannot join

  • Contraindications to regional anesthesia or peripheral nerve blocks
  • Allergy to local anesthetics or any of the study medications
  • Severe hepatic or renal insufficiency
  • Chronic opioid consumption
  • Patient with difficulty comprehending visual analogue scale pain scores
  • Pre-existing lower extremity neurologic abnormalities
  • Patients classified as American Society of Anesthesiologists score 3 or 4
  • Language/communication barrier

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • University of Calgary/AB Hip and Knee Clinic

    Calgary, Alberta

Other trials in Canada

About this study

Official title: Infiltration Between the Popliteal Artery and the Capsule of the Knee (iPACK) With Local Infiltration of Analgesia (LIA) and Adductor Canal Block (ACB) Improves Postoperative Pain in Total Knee Arthroplasty: A Randomized Controlled Trial

Total knee arthroplasty is an effective surgical intervention for patients with chronic osteoarthritis commonly performed worldwide. Postoperative pain management has been a key focus in patient care for this procedure. Poorly controlled pain following total knee arthroplasty is associated with decreased ambulation, increased length of hospital stay, increased complications (particularly related to significant opioid use), and overall suboptimal patient recovery. Appropriate postoperative pain management utilizing motor sparing peripheral nerve blocks and periarticular injections has been shown to provide faster, more optimized patient recovery and reduced hospital length of stay in patients undergoing total knee arthroplasty.

Adductor canal block (ACB) is a well-studied peripheral nerve block performed for analgesia following total knee arthroplasty. ACB is an effective component of multimodal analgesia providing improved pain control to the peripatellar and intra-articular aspect of the knee joint while largely preserving the strength of the quadriceps muscles1. In addition, perioperative local infiltration analgesia (LIA) performed by the orthopaedic surgical team is a common practice that has been shown to improve short-term postoperative pain relief and reduce total systemic opioid consumption during hospital stay2 for total knee arthroplasty.

Read more

The Infiltration between the Popliteal Artery and Capsule of the Knee (iPACK) block is a newly described regional anesthesia technique for postoperative analgesia in total knee arthroplasty, performed under ultrasound guidance. It targets the articular branches of the tibial, common peroneal, and obturator nerves in the popliteal region, and aims to provide analgesia to the posterior aspect of the knee joint without compromising lower extremity motor function following total knee arthroplasty.

This study aims to determine whether the IPACK block provides additional analgesia (in combination with ACB + LIA) for total knee arthroplasty surgeries. The study will examine how much additional analgesia IPACK provides in the context of an already-optimized regional anesthesia pathway for total knee arthroplasty, which uses ACB + LIA, both modalities that have reasonable existing evidence.

Read the detailed description

Currently, limited studies exist in the literature regarding the use of iPACK for analgesia in total knee arthroplasty. Specific studies on the addition of iPACK to ACB or LIA demonstrate clinically significant reductions in pain scores for patients undergoing total knee arthroplasty. However, no studies currently examine the use of iPACK in the setting of patients receiving both ACB and LIA, as a fully optimized regional anesthesia "bundle" for postoperative analgesia in total knee arthroplasty. As such, this study aims to determine whether the addition of the iPACK block, in combination with ACB and LIA, will improve analgesia compared to what is provided by ACB and LIA alone.

Rationale for study:

The IPACK block, based on limited existing literature, seems to provide superior analgesia with minimal complications following total knee arthroplasty.

This study aims to determine whether the IPACK block provides additional analgesia (in combination with ACB + LIA) for total knee arthroplasty surgeries. The study will examine how much additional analgesia IPACK provides in the context of an already-optimized regional anesthesia pathway for total knee arthroplasty, which uses ACB + LIA, both modalities that have reasonable existing evidence.

Determining the effectiveness of IPACK in addition to the already validated multimodal analgesia including ACB and LIA for improving postoperative pain may further improve clinical outcomes in patients undergoing total knee arthroplasty. This may reduce postoperative opioid requirements and its side effects, increase patient satisfaction, and decrease morbidity and mortality associated with a prolonged hospital stay.

The demand for total knee arthroplasty is predicted to increase in the upcoming years owing to an aging population and increased prevalence of osteoarthritis worldwide. The growing number generates multiple issues to the healthcare system, mainly the additional pressure to decrease the already unsustainable high healthcare costs. The role of iPACK as an additional component of pain management may be the key to providing a safe and cost-effective healthcare service to patients undergoing total knee arthroplasty.

Study Question Does the addition of the iPACK block, in combination with ACB and LIA, improve postoperative analgesia and clinical outcomes compared to ACB and LIA alone in patients undergoing total knee arthroplasty?

Hypothesis:

Investigators hypothesize that the addition of this newly described, motor-sparing iPACK block will significantly improve analgesia and clinical outcomes in patients undergoing total knee arthroplasty.

Study Design :

To determine the effectiveness of the iPACK block as a component of multimodal analgesia for patients undergoing total knee arthroplasty, this study will be a prospective double blinded randomized controlled trial where the patients will be randomized to 2 groups:

Group A will receive perioperative ACB, LIA, and sham IPACK block. Group B will receive perioperative ACB, LIA, and real IPACK block.

In addition, all patients will receive a standard spinal anesthetic as per our institutional protocol, along with procedural IV sedation at the discretion of the attending anesthesiologist. Local infiltration analgesia will be administered by the orthopaedic surgeon as per standard practice. ACB and iPACK block will be performed by the anesthesiologist immediately preoperatively under ultrasound guidance as follows:

All patients in the study will receive ACB, performed by an experienced anesthesiologist, as conventionally described, using full aseptic technique, in-plane ultrasound guidance, identification of the superficial femoral artery, sartorius muscle and adductor canal. Local anesthetic (0.25% bupivacaine + 2.5mcg/mL epinephrine + 50mcg/mL preservative-free dexamethasone x 15mL) will be infiltrated with real-time ultrasound visualization, needle approach lateral to medial, with incremental injection, intermittent aspiration, and confirmation of adequate local anesthetic spread.

Patients in group A will receive a sham iPACK block while those in group B will receive a real iPACK block. Both sham and real iPACK blocks will be performed by an experienced anesthesiologist, blinded to the intervention. Real and sham iPACK blocks will be performed as conventionally described with ultrasound guidance (initial approach 1 finger breadth above the patella, if this approach fails, subsequent attempt at level of femoral condyles/bicondylar approach). All sham and real iPACK blocks will be done with full aseptic technique, in-plane ultrasound guidance, identification of popliteal artery/vessels, femur, and sciatic nerve. Normal saline x 20mL (Group A), or local anesthetic x 20mL (Group B - 0.25% bupivacaine + 2.5mcg/mL epinephrine + 50mcg/mL preservative-free dexamethasone), will be infiltrated with real-time ultrasound visualization, needle approach medial to lateral, with incremental injection, intermittent aspiration, and confirmation of adequate local anesthetic spread.

The study personnel, including research team, anesthesiologists, surgeons, physiotherapists, recovery room and ward nurses, as well as patients will be blinded to the group allocation. Anesthesia assistants not involved in study data collection or patient care will prepare the sham or real local anesthetic injectate solution for iPACK block. Syringes will be prepared immediately after randomization and before block placement and provided to the blinded anesthesiologist. Pain scores and opioid consumption, length of stay, and other data will be collected and assessed in person by a member of the research team or patient care team who is blinded to study interventions.

Study procedure:

Participating orthopaedic surgeons will identify eligible patients and introduce them to the study and research team at Alberta Hip and Knee Clinic (AHKC). Research staff will follow recruitment procedure and seek informed consent from patients at AHKC. Participation in this study will remain completely voluntary without any pressure from investigators. Patients' questions will be answered at recruitment session. Upon recruitment, patients will be asked to complete Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Knee Society Scoring (KSS).

Study participants will be assigned study identification and get randomized in to two treatment arms.

The statistician who run randomization would only know study identifications and stay blinded to patients' treatment arms. Hospital data will be used to know Length of Stay (LOS) and opioid consumption at hospital. A physiotherapist will perform Timed Up and Go test and Range of Motion (ROM) Pre and post-operatively at Peter Lougheed Hospital. Pain score will be recorded using Visual analogue scale 4 hours postoperatively and at discharge. Emergency room visit or 30-day readmission will be accessed through Alberta Bone and Joint Health Institute (ABJHI) data repository. "Unanticipated complications of iPACK block" and "technical difficulties with performing the iPACK block" will be recorded by the study anesthesiologist.

Being tested
Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone), Sham iPACK block with 20ml normal saline
Medical subject headings
Agnosia, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)Drug

    Also called real iPACK block with local anesthesia

    real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone

  • Sham iPACK block with 20ml normal salineDrug

    Also called sham iPACK block with Normal saline

    Sham iPACK block with 20 ml Normal saline

Study groups in NCT04635176
Study groupRoleWhat they receive
Sham iPACK blockPlacebo comparatorThis groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia+ sham iPACK block with 20 mL of normal saline.
Receives: Drug: Sham iPACK block with 20ml normal saline
Real IPACK block.Active comparatorThis groups will receive the adductor canal block with the local anesthetic (15 mL of 0.25% bupivacaine + 2.5 mcg/mL epinephrine + 50 mcg/mL preservative-free dexamethasone) and local infiltration of analgesia + real iPACK block with 20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone
Receives: Drug: Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing pain scores using the visual analogue scale between 2 groups

    Visual analogue scale is a tool to measure intensity of pain in human. It is numeric (0-100);A higher score indicates greater pain intensity.

    Measured: 4 hours after surgery

  2. Comparing pain scores using the visual analogue scale between 2 groups

    Visual analogue scale is a tool to measure intensity of pain in human. It is numeric (0-100);A higher score indicates greater pain intensity.

    Measured: 24 hours after surgery

  3. Comparing total opioid consumption between 2 groups

    Opioid consumption will be compared between two groups by measuring how many milligrams opioids patients consume in each group, the total dose of opioids consumed by patients will be converted to oral morphine dose equivalents in milligrams, and this mg value will be compared between the groups. The opioid can refer to morphine or oxycodone or hydromorphone or codeine any kind of opioid-type medication. There is a standard conversion of any other opioid potency to "morphine equivalents" (eg: hydromorphone is 5x more potent than morphine).

    Measured: During 24 hours after surgery

  4. Comparing total length of hospital stay

    Comparing total length of hospital stay

    Measured: 20-48 hours after surgery

  5. Timed Up and Go test results

    Timed Up and Go test results

    Measured: pre-intervention

  6. Timed Up and Go test results

    Timed Up and Go test results

    Measured: Up to 24 hours after surgery

  7. Comparing knee Range of Motion (ROM)

    Comparing knee Range of Motion (ROM)

    Measured: pre-intervention

  8. Comparing knee Range of Motion (ROM)

    Comparing knee Range of Motion (ROM)

    Measured: Up to 24 hours after surgery

  9. Comparing patient satisfaction using Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    The WOMAC is a patient reported outcome questionnaire, consisting 24 items divided into three subscales: 1) Pain (5 items), 2) Stiffness (2 items) and 3) Physical Function (17 items). A total WOMAC score is created by summing the items for all three subscales. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations. Previous assessment has supported the internal consistency of the WOMAC subscale.

    Measured: Up to 24 hours after surgery

  10. Comparing patient satisfaction using Knee Society Scoring (KSS)

    The Knee Society Scoring system is both physician and patient-derived. It includes versions to be administered pre-operatively and post-operatively. It has an initial assessment of demographic details, including an expanded Charnley Functional classification. The objective knee score, completed by surgeon, includes a Visual Analogue Scale score of pain walking on level ground and on stairs or inclines, as well as an assessment of alignment, ligament stability, and Range Of Motion. The KSS System is a validated instrument based on surgeon and patient generated data, adapted to the diverse lifestyles and activities. The greater score associated with higher satisfaction.

    Measured: Up to 24 hours after surgery

Secondary outcomes (5)
  1. Number pf participants returning to emergency room in the hospital

    Number pf participants returning to emergency room in the hospital

    Measured: Within 30 days after surgery

  2. Incidence of the unanticipated motor block from iPACK intervention by a questionnaire filled out by the attending anesthesiologist

    Incidence of the unanticipated motor block from iPACK intervention by a questionnaire filled out by the attending anesthesiologist

    Measured: Up to 24 hours after surgery

  3. Incidence of other unanticipated complications of iPACK intervention by a questionnaire filled out by the attending anesthesiologist

    Incidence of other unanticipated complications of iPACK intervention by a questionnaire filled out by the attending anesthesiologist

    Measured: Up to 24 hours after surgery

  4. Incidence of technical difficulties experienced by a questionnaire filled out by the attending anesthesiologist on the day of surgery

    Incidence of technical difficulties experienced by a questionnaire filled out by the attending anesthesiologist on the day of surgery

    Measured: 24 hours after surgery

  5. Comparing duration (in minutes) of tourniquet use during surgery between two groups

    Tourniquets are tight bands used to completely stop the blood flow to a wound. Duration of its use will be noted at operation room in minutes.

    Measured: During surgery time

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2020
  2. Study start30 Oct 2022
  3. Primary completion27 May 2026
  4. Study completion27 May 2026

Why it stopped: The study has been stopped due to logistical reasons at the clinical site.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
Group A will receive perioperative ACB, LIA, and sham IPACK block. Group B will receive perioperative ACB, LIA, and real IPACK block.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04635176
Sponsor's protocol ID
"REB20-1633"
Status last verified
May 2026
First submitted
23 Oct 2020
Last updated
1 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Real iPACK block (20 mL of 0.25% bupivacaine, 2.5mcg/mL epinephrine, and 50mcg/mL preservative-free dexamethasone) in people with Osteo Arthritis Knee and Analgesia, run by University of Calgary at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: The study has been stopped due to logistical reasons at the clinical site.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparing pain scores using the visual analogue scale between 2 groups (time frame: 4 hours after surgery). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in